SCHEMBL2360362

SCHEMBL2360362

COc1ccc(-c2noc(-c3cc(C)[nH]n3)n2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.71
POLB P06746 1/20 0.71
RAB9A P51151 8/20 0.59
NPC1 O15118 7/20 0.59
SMN1; SMN2 Q16637 5/20 0.59
NPSR1 Q6W5P4 2/20 0.59
S1PR1 P21453 1/20 0.56
NR1H4 Q96RI1 1/20 0.56
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
LMNA P02545 2/20 0.51
HPGD P15428 3/20 0.51
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 2/20 0.51
TP53 P04637 5/20 0.50
NFKB1 P19838 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
HSD17B10 Q99714 1/20 0.50
CASP3 P42574 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13362298 0.85 MAPT (0.56) MAPTPOLBRAB9ANPC1SMN1; SMN2
SCHEMBL516913 0.85 MAPT (0.53) MAPTPOLBRAB9ANPC1SMN1; SMN2
SCHEMBL2640808 0.83 MAPT (0.52) MAPTPOLBRAB9ANPC1SMN1; SMN2
SCHEMBL2358668 0.83 MAPT (0.51) MAPTPOLBRAB9ANPC1SMN1; SMN2
SCHEMBL2360413 0.81 HTT (0.50) MAPTPOLBRAB9ANPC1SMN1; SMN2
SCHEMBL2360887 0.81 MAPT (0.63) MAPTPOLBRAB9ANPC1SMN1; SMN2
SCHEMBL2360618 0.81 NPC1 (0.65) MAPTPOLBRAB9ANPC1NPSR1
SCHEMBL24783657 0.80 LMNA (0.65) MAPTPOLBRAB9ANPC1SMN1; SMN2
SCHEMBL2640845 0.80 MAPT (0.49) MAPTPOLBRAB9ANPC1SMN1; SMN2
SCHEMBL2640759 0.80 LMNA (0.59) MAPTPOLBRAB9ANPC1S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301122-A1 HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-12-08 US disclosed
US-20110301122-A1 HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-12-08 US disclosed
EP-2356112-A1 HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS Bayer Schering Pharma Aktiengesellschaft (DE) 2011-08-17 EP disclosed
WO-2010054764-A1 HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-20 WO disclosed
WO-2010054764-A1 HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301122-A1 HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS HIF1AN, HIF1A, VHL MAPT 4432/4885POLB 747/4885RAB9A 4372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.